头颈部癌溶瘤病毒疗法的现状
The current status of oncolytic viral therapy for head and neck cancer.
作者信息
Old Matthew O, Wise-Draper Trisha, Wright Chadwick L, Kaur Balveen, Teknos Theodoros
机构信息
Department of Otolaryngology - Head and Neck Surgery, The James Cancer Hospital and Solove Research Institute, Wexner Medical Center at The Ohio State University, USA.
Division of Hematology-Oncology, Department of Internal Medicine, University of Cincinnati, USA.
出版信息
World J Otorhinolaryngol Head Neck Surg. 2016 Jul 22;2(2):84-89. doi: 10.1016/j.wjorl.2016.05.009. eCollection 2016 Jun.
OBJECTIVE
Cancer affects the head and neck region frequently and leads to significant morbidity and mortality. Oncolytic viral therapy has the potential to make a big impact in cancers that affect the head and neck. We intend to review the current state of oncolytic viruses in the treatment of cancers that affect the head and neck region.
METHOD
Data sources are from National clinical trials database, literature, and current research.
RESULTS
There are many past and active trials for oncolytic viruses that show promise for treating cancers of the head and neck. The first oncolytic virus was approved by the FDA October 2015 (T-VEC, Amgen) for the treatment of melanoma. Active translational research continues for this and many other oncolytic viruses.
CONCLUSION
The evolving field of oncolytic viruses is impacting the treatment of head and neck cancer and further trials and agents are moving forward in the coming years.
目的
癌症经常影响头颈部区域，并导致显著的发病率和死亡率。溶瘤病毒疗法有可能对影响头颈部的癌症产生重大影响。我们打算综述溶瘤病毒在治疗影响头颈部区域癌症方面的现状。
方法
数据来源为国家临床试验数据库、文献和当前研究。
结果
过去和正在进行的许多溶瘤病毒试验显示出治疗头颈部癌症的前景。第一种溶瘤病毒于2015年10月获得美国食品药品监督管理局（FDA）批准（安进公司的T-VEC）用于治疗黑色素瘤。针对这种及许多其他溶瘤病毒的积极转化研究仍在继续。
结论
不断发展的溶瘤病毒领域正在影响头颈部癌症的治疗，未来几年将有更多试验和药物问世。
Zotero 插件